Tricomegalia secundaria a cetuximab

Cetuximab-Associated Elongation of the Eyelashes

“…[8,12,15,16,19] Mucocutaneous reactions to EGFR inhibitors are summarized in table I. [1][2][3][4][5][6]9,11,14,15,17,19,20,[22][23][24][25][26][27][28][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] These include not only increased (hypertrichosis) and decreased (alopecia) Acral fissures Fissures occur on the hands and feet, fingers (tips and interphalangeal joints), and toes. [8,15,26] Indeed, the papulopustular eruption has been associated with favorable tumor response, lengthening of time to progression, and improved overall survival.…”

“…Congenital eyelash trichomegaly has been observed in patients with Oliver-McFarlane syndrome and type I oculocutaneous albinism. [1][2][3][4][5]14,24,[36][37][38][39][40][41] The drug is usually delivered at an initial dose of 400 mg m 2 followed by weekly infusions of 250 mg m 2 ; [1,3,4] the patients may also be receiving radiotherapy [3] or irinotecan. [33] Similar to our patient, eyelash trichomegaly has been described in other individuals receiving cetuximab.…”

“…[19,22,39,42,45] Since these agents inhibit the EGFR via different mechanisms, the resultant eyelash trichomegaly probably results from a downstream effect secondary to the receptor inhibition. [11,36,38] Eyelash trichomegaly has occurred most commonly in patients with colorectal carcinoma [1,2,4,5,[36][37][38] and lung cancer [5,6,19,22,31,[33][34][35]42] who have been treated with EGFR inhibitors; cetuximab-induced long eyelashes have also been observed in individual patients with either oropharyngeal squamous cell carcinoma [3] or porocarcinoma. It has been postulated that premature maturation of the hair follicle epithelium cells with subsequent terminal differentiation results from dysregulated keratin gene expression secondary to the inhibition of the EGFR by the drugs.…”

“…EGFR is expressed in the hair follicle epithelium including the outer root sheath. [40] EGFR inhibitor-associated eyelash trichomegaly has been described nearly as often in men as women who have been treated with cetuximab [1,[3][4][5]24,[36][37][38]40] and three times as often in women than men who have received erlotinib. [3,4,10,11,21,38,46,47] A recent study shows that while trichomegaly becomes more prominent over time, folliculitis diminishes, and the authors speculate that persistent EGFR blockade could lead to a downregulation of EGFR expression on keratinocytes.…”

“…The median onset time is 12 weeks. Hair changes associated with epidermal growth factor receptor inhibitors Alopecia [17,24,30] Extremities: arms [5] or arms and legs [5] Scalp: diffuse [9,23,24] or frontal (androgenic alopecia-like) [5,11] Color [31] Eyelashes: darkening [31][32][33] Scalp hair: darkening [31] or becoming fair, red, and gray [5] Eyelashes [20] Aberrant [34] Brittle [34] Coarse [32][33][34][35] Curling [19,20,31,33,35,36] Darkening [31][32][33] Irregular [34] Madarosis (loss of eyelashes) [28] Rigid [36] Thick [19,33] Tortuous [19] Trichiasis (misdirectional growth of eyelashes toward the globe) [2,22,34,35,37] Trichomegaly [1][2][3][4]…”